Syntagon to offer “substantial cost savings” to clients
Syntagon is implementing a strategic pricing initiative to give “substantial cost savings” to pharma and biotech companies taking compounds into Phase I and II clinical trials.
Acknowledging the pressures facing the industry, Syntagon is passing on to customers some of savings it has made by establishing a unit in Riga, Lativia and sourcing operation in Shanghai, China.
“Now, more than ever, customers are under growing pressure to make their limited resources stretch further”, explained John Cameron, director of sales and marketing at Syntagon.
Furthermore, Syntagon believes its experience manufacturing and analysing active pharmaceutical ingredients (API) for Phase I and II trials helps it increase workflow and improve efficiencies.
